ASTS
VIR
Deal’s in the bag
Vir Biotechnology just said its global collaboration and licensing agreement with Astellas has closed, after the HSR waiting period expired. Translation: the paperwork maze is over, and the companies can start acting like this partnership is actually a thing — not just a fancy press release with a PowerPoint deck.
Why investors should care
This isn’t just a “we’re excited to work together” moment. Vir gets:
- a $240 million upfront payment
- a $75 million equity investment at $10.36 per share
- a $20 million near-term milestone payment
- a 50/50 split of U.S. profit and loss with Astellas
- up to $1.37 billion more in milestones, plus tiered double-digit royalties outside the U.S.
That’s a pretty chunky vote of confidence for VIR-5500, Vir’s PSMA-targeted, PRO-XTEN dual-masked T-cell engager for metastatic prostate cancer. In biotech, cash plus validation is the dream combo — like getting both the green light and the snack budget.
The bigger picture
For Vir, this deal does two useful things at once: it helps fund development and it brings in a heavyweight partner. For investors, that can mean less financial pressure and a clearer path for the asset — though the usual biotech reality check still applies: the real test is whether VIR-5500 delivers the goods in the clinic.
Big picture: the deal is now official, the money starts flowing, and Vir just turned a collaboration announcement into something with actual economic teeth.